Our data also suggested that blocking the BICC1/LCN2 signaling significantly reduced the microvessel density and tumor volume of PDX models in mice and significantly increased the tumor suppressive effect of gemcitabine, a standard first-line chemotherapy drug for the treatment of PAAD. The gene discussed is BICC1; the disease is pancreatic adenocarcinoma.